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The use of genomic technologies for the molecular
characterization of tumors has propelled our
understanding of cancer biology and is transforming
the way patients with cancer are diagnosed and
treated. genomic analysis of tumors procured from anonymized
patients possessing many different types of cancer. A
Clinical oncology - facing up to the next steps
More than any other field of medicine, oncology has bene-
fited from recent revolutionary advances in nucleic acid
sequencing technology and genomic analysis. For increas-
ingly lower costs and turnaround times, one can profile
the full spectrum of genomic alterations in a tumor sam-
ple, including sequence mutations, copy number changes
and structural rearrangements [1]. Research initiatives
have capitalized on the availability of large numbers of tu-
mors in order to delineate the most frequently mutated
genes and pathways in a range of cancer types. Collectively
these projects, including The Cancer Genome Atlas
(TCGA) and the International Cancer Genome Consor-
tium (ICGC), are characterizing the genomes and epigen-
omes of virtually all common tumor types and producing
a more complete understanding of the biology of cancer
[2-12]. Just as significantly, the introduction of genomic
technologies is transforming clinical practice. Massively
parallel ‘next-generation sequencing’ (NGS) has proven to
be a powerful molecular-diagnostic tool, enabling the iden-
tification of prognostic and predictive biomarkers in indi-
vidual clinical specimens. Challenges for the widespread
implementation of clinical NGS platforms remain, includ-
ing technical, operational, medical and societal consider-
ations. However, by confronting these issues collectively, we* Correspondence: bergerm1@mskcc.org
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benefit to clinical oncology.Opportunities for applying genomics to oncology
Research initiatives such as TCGA and ICGC have led to
an improved understanding of cancer biology through the
major goal of these and similar efforts is to identify genes
and pathways important to cancer progression in order to
design better therapies and interventions. As an early ex-
ample, the identification of recurrent somatic mutations
in the serine/threonine-protein kinase B-raf (BRAF) gene
from systematic gene sequencing [13] prompted the de-
velopment of multiple targeted inhibitors of BRAF (not-
ably vemurafenib and dabrafenib), currently approved by
the Food and Drug Administration (FDA) for melanoma
and showing promise in a range of other cancer types
[14,15]. Yet the most exciting and transformative applica-
tions of genomics in oncology involve the use of genomic
techniques to analyze clinical tumor specimens. First, by
sequencing tumors obtained from patients treated with
approved and experimental targeted therapies, one can
discover clinical biomarkers that predict outcomes and
therapeutic response. Second, by prospectively sequencing
patients’ tumors as part of their care, one can select per-
sonalized therapies to employ based on the individual mo-
lecular profile of the tumors. We discuss both of these
opportunities below.Phenotype to genotype: retrospective sequencing for
biomarker discovery
Genomic alterations that predict the likelihood of re-
sponse to therapeutic agents, especially novel targeted
therapies, serve as powerful biomarkers and major de-
terminants of treatment decisions. In many cases, the
retrospective characterization of tumors procured from
patients with documented clinical outcomes has revealedCentral Ltd. The licensee has exclusive rights to distribute this article, in any medium,
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discovery of epidermal growth factor receptor (EGFR)
mutations in lung cancer was prompted by the clinical
observation that a subset of patients exhibited a major
response when administered tyrosine kinase inhibitors
in clinical trials [16-18]. Today, a growing number of
clinical trials in oncology are designed with correlative
sequence analysis for biomarker discovery written into
the study.
Recently, the analysis of ‘exceptional responders’ - cancer
patients with an unexpected complete and/or durable re-
sponse to therapy - has proven to be particularly effective.
Studying exceptional responders can reveal specific gen-
omic alterations accounting for their exquisite sensitivity
to certain drugs. One can hypothesize that other patients
whose tumors bear similar alterations will benefit from
the same drugs. Recent successful applications of whole-
genome or exome sequencing in exceptional responders
include the identification of tuberous sclerosis 1 protein/
hamartin (TSC1) and serine/threonine-protein kinase
mTOR/mammalian target of rapamycin (MTOR) muta-
tions in bladder cancer patients responding to everolimus
and a mutation in serine/threonine-protein kinase A-Raf
(ARAF) in a lung cancer patient responding to sorafenib
[19-21]. Owing to the promise of this approach, the US
National Cancer Institute has launched a program to col-
lect tissue samples and clinical data from up to 200 excep-
tional responders in an attempt to explain isolated
responses to drugs that otherwise failed clinical trials [22].
Retrospective analysis of clinical tumor specimens can
also reveal mechanisms of acquired resistance to targeted
therapies. By collecting and comparing samples before
treatment and at progression, one can discover genetic al-
terations that emerge during drug exposure and confer
drug resistance. This approach has led to the identification
of a broad spectrum of resistance mechanisms arising dur-
ing inhibition of EGFR in lung cancer and during inhib-
ition of BRAF in melanoma [23-27]. Other examples
include single-nucleotide mutations conferring resistance
to imatinib in leukemia [28], enzalutamide in prostate
cancer [29] and anti-estrogen therapy in breast cancer
[30,31]. Resistance mutations might be second hits to the
drug target itself, could affect downstream genes that re-
activate the targeted pathway or might activate alternative
pathways that bypass or counteract the effects of the drug.
The identification of such mutations in tumors can point
to novel combination strategies and/or lead to the devel-
opment of new, more potent drugs.
Genotype to phenotype: prospective sequencing for
clinical diagnosis
Based in part on the identification of predictive clinical
biomarkers from retrospective analyses, there are several
tumor types for which prospective mutation profiling asa diagnostic tool is now a standard of care. Patients with
metastatic non-small cell lung cancer are routinely tested
for EGFR mutations and rearrangements of the gene
encoding the ALK tyrosine kinase receptor/anaplastic
lymphoma kinase (ALK) to guide treatment. If a sensitiz-
ing mutation in EGFR or a rearrangement in ALK is iden-
tified, treatment with an inhibitor of EGFR or ALK is
recommended. While drugs targeting these alterations are
FDA approved, several targeted agents have demonstrated
activity against lung cancers harboring other genetic alter-
ations. For instance, cabozantinib has demonstrated activ-
ity in lung cancers harboring rearrangements in the gene
encoding the tyrosine-protein kinase receptor Ret (RET),
and crizotinib has demonstrated activity in lung cancers
harboring amplifications in the gene encoding the hepato-
cyte growth factor receptor (MET) or rearrangements in
the ROS1 gene encoding tyrosine-protein kinase ROS
[32-34]. For patients with metastatic colorectal cancer,
testing for the presence or absence of hotspot mutations
in the genes encoding the GTPases KRAS and NRAS is
recommended to assess whether patients might benefit
from EGFR-directed monoclonal antibody therapies utiliz-
ing the drugs cetuximab or panitumumab. For patients
with melanoma harboring V600 mutations in BRAF, treat-
ment with vemurafenib or dabrafenib is recommended.
Molecular-diagnostics labs have traditionally relied on
low-throughput, mutation-specific methods for DNA pro-
filing in patients because there were so few actionable
genetic alterations that altered treatment decisions in the
clinical care of patients. However, given the growing num-
ber of biomarkers and clinical trials studying targeted
agents, the approach of testing one mutation at a time is
unsustainable. NGS-based assays are replacing these
more-focused tests in both academic and commercial
settings. The benefits of this are obvious. First, a single
NGS test can encompass all ‘actionable’ targets, eliminat-
ing the need for multiple parallel tests for different muta-
tions and enabling more-efficient workflows and tissue
utilization. Second, the entire coding sequence of target
genes can be assayed (rather than only pre-specified sites),
facilitating the detection of both common and rare muta-
tions in oncogenes and tumor-suppressor genes. Third,
NGS enables the detection of additional classes of genomic
alterations, such as copy number changes and structural
rearrangements. Finally, subclonal events in heterogeneous
tumors can be detected more reliably owing to the high
sensitivity afforded by NGS.
Some academic centers have implemented pilot pro-
grams for the comprehensive genomic characterization of
tumors from selected patients by means of whole-genome
or exome sequencing (DNA-Seq) and transcriptome se-
quencing (RNA-Seq) [35,36]. Through expert review and
curation of these expansive data sets, clinically relevant al-
terations can often be identified that direct treatment with
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boards’ composed of clinicians and scientists trained in
medical oncology, cell biology, genomics and bioinfor-
matics, as pioneered by the University of Michigan and
elsewhere, are forming at many leading cancer centers
to review and interpret clinical genomic data in order to
recommend and guide therapy [35]. These organizations
also serve to educate members of the medical commu-
nity as to the power and intricacies of genomic analysis
and are catalyzing the development of communal frame-
works for the clinical annotation and interpretation of
somatic alterations.
Owing to practical barriers in the implementation of
this comprehensive approach for all patients, namely its
high cost and low throughput, large-volume molecular-
diagnostics labs have focused instead on targeted se-
quencing of key cancer-associated genes as a feasible
and economical alternative [37-42]. Furthermore, the
deeper sequence coverage afforded by targeted sequen-
cing enables low-allele-frequency mutations in heteroge-
neous or low-purity tumors to be detected with greater
sensitivity. Multiplexing through the use of sample ‘bar-
codes’ permits many tumors to be profiled in a single
NGS run [43]. This has enormous implications for the
design and implementation of clinical trials in oncology.
By systematically screening large numbers of patients
with metastatic disease for common and rare ‘druggable’
mutations, patients can be pre-identified for future trials
involving the most promising targeted therapies, and
new trials can rapidly accrue patients with the greatest
likelihood of exhibiting a clinical response. Novel clinical
trial designs have emerged as a direct result of advances
in molecular profiling. One such trial, often called a ‘bas-
ket’ study, involves a single targeted drug administered
to patients across many different tumor types (baskets) that
share a common genomic profile. Other clinical protocols
utilize centralized NGS-based diagnostic testing to assign
patients recruited through cooperative groups to multiple
separate trials involving targeted agents, pioneered by the
NCI-MATCH study and others [22].
Challenges in applying genomics to oncology
In order for genomic insights and technologies to be truly
transforming in oncology, we must develop and imple-
ment high-throughput molecular-diagnostic tests that ex-
hibit both clinical validity and clinical utility. Assays must
achieve rapid turnaround times at low cost, encompass all
classes of sequence-based mutations and structural alter-
ations, and operate on small biopsies, formalin-fixed par-
affin embedded (FFPE) tissue and cytological specimens
[44]. Furthermore, results must be annotated with associ-
ated genomic and clinical data pertaining to the specific
set of mutations observed in each individual tumor in
order for oncologists to make the most-informed treatmentdecisions. This endeavor, although very promising, is
fraught with challenges.
Technical and operational considerations
The development of assays compatible with low-quality
specimens and low input DNA amounts remains a tech-
nical challenge. For these suboptimal samples that are
routinely encountered in clinical settings, comprehensive
genomic analysis is not always possible. PCR-based cap-
ture technologies can produce deep-coverage sequence
data with very little DNA, but targets are generally small,
and the detection of copy-number alterations and struc-
tural rearrangements is compromised. With slightly more
DNA, hybridization-based capture assays enable an ex-
panded number of target genes and alteration types but
still can exclude important regions of the genome. Even
whole-exome sequencing, encompassing all protein-
coding genes in the genome, will miss many structural
alterations as well as nucleotide substitutions involving
regulatory regions such as the promoter of the gene en-
coding telomerase reverse transcriptase (TERT), which
rank among the most frequently observed mutations in
all cancers [45-47]. Individual clinical labs are left to
choose how many (and which particular) genes to se-
quence based largely on their anticipated volume and
diversity of cases, desired turnaround time and cost,
and bioinformatics capabilities.
Indeed, providing support for bioinformatics represents
one of the most significant challenges for the widespread
implementation of clinical NGS workflows. Historically,
pathology departments at hospitals and academic cancer
centers have not employed large numbers of bioinformati-
cians. As a result, the recruitment and training of capable
computational staff is of utmost importance in order to
develop, maintain and deploy pipelines for the analysis of
clinical cancer genomic data. The bioinformatics algo-
rithms and software that comprise these pipelines are con-
tinually evolving, with new tools emerging constantly,
making it difficult to standardize analysis procedures.
Additionally, issues pertaining to the management and
storage of large data files and the establishment of high-
performance computing infrastructures for data processing
and analysis represent new challenges for clinical labs and
departments. The complexity of most hospital information
systems could further hinder efforts to deposit molecular-
diagnostic results into a patient’s electronic health record
and to link genomic data to other clinical, phenotypic and
demographic data. This integration of genomic and clin-
ical data is crucial for the long-term goal of achieving bet-
ter outcomes for patients with cancer.
In order for clinical NGS results to be used by oncolo-
gists to influence treatment decisions, tests must be per-
formed in Clinical Laboratory Improvement Amendments
(CLIA)-compliant laboratories, governed by the Centers
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extensive documentation and technical validation of sensi-
tivity, accuracy and reproducibility are required before any
genomic assay can be prospectively administered and/or
billed to healthcare payers. While some institutions have
initiated programs where large-scale genomic analysis is
performed in research labs, followed by confirmatory test-
ing in CLIA-compliant labs, this approach is unsustainable
when NGS-related costs cannot be recovered through
reimbursement.
Clinical considerations
While use of comprehensive molecular profiling has pro-
duced success stories, such as the remarkable responses to
erlotinib for patients with EGFR-mutant lung cancers or
crizotinib for patients with ALK-positive lung cancers,
these findings have also resulted in challenges and ques-
tions concerning how to proceed.
First, comprehensive molecular profiling using any of
the assays or technologies described above will yield in-
formation about both well-known molecular drivers in
cancer and countless more alterations whose biological
and clinical significance is unclear. It is often difficult for
a clinician to make the crucially important distinction
between key ‘driver alterations’ that should impact treat-
ment and less-relevant ‘passenger mutations’. Some pub-
licly available knowledge banks have been created to
help doctors and patients interpret the significance of
many commonly seen alterations, such as My Cancer
Genome developed at the Vanderbilt-Ingram Cancer
Center. While these sites are excellent resources to learn
about clinically and pathologically annotated alterations,
they are not comprehensive and cannot be expected to
include information on all possible alterations that a clin-
ician could encounter. Similarly, there is little guidance for
the management of patients with multiple driver alter-
ations in more than one gene. One might rationally as-
sume to administer combinations of targeted therapies;
however, without knowing the toxicity profiles or optimal
dosing and scheduling of the combination, this strategy is
problematic.
Also, the use of targeted therapies in the treatment of
cancer is rarely straightforward, even in the presence of
individual well-characterized driver alterations. NGS
testing of heterogeneous tumors can reveal targetable
mutations at subclonal allele frequencies, the clinical
consequences of which are uncertain. Furthermore, the
biological and clinical context can be extremely import-
ant. For instance, while patients with melanomas har-
boring BRAF V600E mutations almost always respond
to inhibitors of BRAF, this direct treatment approach
has not been replicated for patients with BRAF-mutant
colon cancers. Colon cancers harboring BRAF V600E
mutations do not respond to single-agent vemurafenib -this is thought to be related to feedback reactivation of al-
ternative or upstream signaling pathways [48,49]. Studies
are ongoing to explore and exploit these mechanisms by
using combination therapy in the treatment of BRAF-
mutant colon cancer. In order for clinicians to make in-
formed treatment decisions, molecular-diagnostic reports
must display alongside each mutation disease-specific
contextual annotations in a succinct and easily digestible
form.
Which specimens to analyze and when to analyze
them are also questions that arise in the clinical care of
patients. Given emerging data about tumor heterogen-
eity in metastatic disease, it is unclear that a single bi-
opsy of a single site of metastatic disease will accurately
capture driver alterations that would most impact a pa-
tient’s clinical care. Additionally, it is unclear that biop-
sies obtained at the time of diagnosis remain relevant
after patients have developed acquired resistance to tar-
geted therapies or have developed recurrent disease after
initial therapies for early-stage cancer. While biopsies
taken at the time of acquired resistance are becoming
standard in many clinical trials of targeted agents, these
biopsies are not routinely performed in the clinical care
of patients.
Most importantly, targeted therapies are not curing
patients of their cancer. While targeted therapies have
yielded promising, dramatic and life-changing responses
for many patients with cancer, the reality is that these re-
sponses are generally short lived. For instance, the average
responses to erlotinib among patients with EGFR-mutant
lung cancer and vemurafenib for patients with BRAF
V600E mutant melanoma are 11 months and 5 months,
respectively [14,50]. All of these patients will ultimately
acquire resistance and succumb to their disease. In fact,
some have questioned the cost effectiveness of targeted
therapies, given the rare frequency of some driver muta-
tions and the high cost of these therapies [51].
Societal considerations
The societal and ethical implications of comprehensive
genetic testing must also be considered in this rapidly
changing technological landscape. While focused diag-
nostic tests including targeted ‘hotspot’ panels utilize
only tumor-derived DNA, more-comprehensive NGS ap-
proaches typically require germline DNA to distinguish
between novel somatic mutations and inherited variants.
The use of germline DNA poses the risk that incidental
findings could be revealed relating to inherited suscepti-
bility to cancer or other diseases. This has led institu-
tions to consider different strategies of informed consent
and pre-test genetic counseling. However, given the time
pressures of clinical care, the ability to perform thorough
genetic counseling in a routine fashion is limited. For
those patients in whom an inherited predisposition to
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patients’ autonomy and privacy, protect them and their
families from possible discrimination and also manage
the unintended emotional and psychological consequences
that such a diagnosis brings.
Additionally, it remains unclear whether NGS-based
molecular profiling is cost-effective or even clinically ef-
fective in the care of patients outside of lung cancer, mel-
anoma and colon cancer. As a result, insurance companies
have demonstrated a reluctance to reimburse the cost of
comprehensive testing in many tumor types. While large
academic cancer centers might be able to offset costs tem-
porarily through grants and philanthropic contributions,
broad access to these tests for patients in the community
has not been achieved. Demonstrating the general clinical
utility of NGS-based molecular profiling is essential in this
regard. A related hindrance is that, when actionable muta-
tions are detected in unexpected tumor types, insurance
companies are often unwilling to reimburse the off-label
administration of therapies approved in other diseases.
Concluding remarks
While genomic knowledge has been successfully applied
to direct clinical decisions in several cases, the implementa-
tion of clinical genomic workflows for oncology has proven
to be complex. Nevertheless, the introduction of NGS tech-
nology has the potential to transform clinical oncology, and
it is incumbent upon clinicians, scientists, regulators, payers
and patients to work collectively to overcome the obstacles
that stand in its path.
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